Athira Pharma Investor Relations Material
Latest events
Status Update
Athira Pharma
Q2 2025
7 Aug, 2025
Q1 2025
9 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Athira Pharma Inc
Access all reports
Athira Pharma Inc., also known as Athira Pharma, is a late clinical-stage biopharmaceutical company focused on developing small molecules aimed at restoring neuronal health and slowing neurodegeneration. The company's leading product candidate, ATH-1017 (Fosgonimeton), is designed to enhance the activity of the hepatocyte growth factor (HGF) and its receptor, MET. The company is headquartered in Bothell, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ATHA
Country
🇺🇸 United States